HUTCHMED (China) reported Phase III SANOVO China trial results showing ORPATHYS plus TAGRISSO produced statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus TAGRISSO alone in treatment-naive patients. The positive PFS differentiation from the control arm is a meaningful efficacy update that could strengthen the clinical and regulatory pathway for the combination.
HUTCHMED (China) reported Phase III SANOVO China trial results showing ORPATHYS plus TAGRISSO produced statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus TAGRISSO alone in treatment-naive patients. The positive PFS differentiation from the control arm is a meaningful efficacy update that could strengthen the clinical and regulatory pathway for the combination.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
strongly positive
Sentiment Score
0.45
Ticker Sentiment
